{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T12:16:00Z","timestamp":1690978560311},"reference-count":9,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.thromres.2013.08.020","type":"journal-article","created":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T08:49:38Z","timestamp":1378025378000},"page":"493-494","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma"],"prefix":"10.1016","volume":"132","author":[{"given":"Yasuyuki","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasuku","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Tsuruoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2013.08.020_bb0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1529-8019.2011.01396.x","article-title":"Steven-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options","volume":"24","author":"Worswick","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.thromres.2013.08.020_bb0010","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrosis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.thromres.2013.08.020_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","article-title":"Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial","volume":"5","author":"Saito","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.020_bb0020","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1172\/JCI22782","article-title":"The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism","volume":"115","author":"Abeyama","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2013.08.020_bb0025","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.thromres.2013.08.020_bb0030","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archdermatol.2011.239","article-title":"High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"147","author":"Nakajima","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.thromres.2013.08.020_bb0035","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1097\/CCM.0b013e3181a55184","article-title":"Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia","volume":"37","author":"Nagato","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.thromres.2013.08.020_bb0040","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0140-6736(99)02658-6","article-title":"Increased serum concentrations of high\u2013mobility group protein 1 in haemorrhagic shock","volume":"354","author":"Ombrellino","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.08.020_bb0045","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3109\/10428194.2012.752081","article-title":"Role of serum high mobility group box 1 in hematological malignancies complicated with systemic inflammatory response syndrome and effect of recombinant thrombomodulin","volume":"54","author":"Inoue","year":"2013","journal-title":"Leuk Lymphoma"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813003757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813003757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T13:24:34Z","timestamp":1539437074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384813003757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0049384813003757"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2013.08.020","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2013.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}